Quarterly ResultMay 13, 2026, 07:32 AM
Abeona Q1 Revenue $8.7M; Net Loss $(17.1)M; In-licenses T-cell Therapy
AI Summary
Abeona Therapeutics reported Q1 2026 net product revenue of $8.7 million, a significant increase from $2.4 million in Q4 2025, driven by ZEVASKYN adoption with three patients treated. The company's net loss widened to $(17.1) million, or $(0.30) per share, compared to $(12.0) million in Q1 2025. Abeona also in-licensed ABO-701, a novel engineered T-cell therapy for prostate cancer, and plans to file an IND in H2 2027, while deprioritizing its ophthalmology programs. Cash, cash equivalents, and short-term investments stood at $168.3 million.
Key Highlights
- Net product revenue was $8.7 million in Q1 2026, up from $2.4 million in Q4 2025.
- Net loss was $(17.1) million, or $(0.30) per share, in Q1 2026.
- Cash, cash equivalents, and short-term investments totaled $168.3 million as of March 31, 2026.
- Three patients were treated with ZEVASKYN in Q1 2026; QTC network expanded to six sites.
- Abeona in-licensed ABO-701, a T-cell therapy for prostate cancer, with a $7.0 million upfront payment.
- R&D expenses were $9.6 million, including the ABO-701 licensing fee.
- SG&A expenses increased to $19.5 million due to ZEVASKYN commercialization efforts.
- Ophthalmology programs were deprioritized as part of portfolio optimization.